JAK2 and myeloid neoplasm: In this study, we examine the efficacy of the USP9X inhibitors WP1130 and G9 on cells expressing wild-type JAK2 or JAK2-V617F, including the ruxolitinib-persistent cells, comparably, to explore the therapeutic potentials of USP9X inhibition against JAK2-V617F-driven myeloid neoplasms.